Clinical trials: Relapsed Cancer
Leukemia, Myelodysplastic Syndromes
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Chemotherapy, such as fludarabine and thiotepa, and radiation therapy may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00112567
- Testing
- fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
This randomized phase III trial is studying tacrolimus, methotrexate, and sirolimus to see how well they work compared to tacrolimus and methotrexate in preventing graft-versus-host disease in young patients who are undergoing…
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00382109
- Testing
- thiotepa, cyclophosphamide, tacrolimus
- Where
- 50 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Children's Oncology Group
Leukemia, Lymphoma
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
- Trial name
- NCT00077493
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- MedImmune LLC
Acute Lymphoblastic Leukemia
A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia
This study is for a population of patients with few or no alternative options that was conducted to determine the response rate to clofarabine.
- Trial name
- NCT00930098
- Testing
- clofarabine
- Where
- 36 sites in Austria, France and 4 more
- Volunteers
- 74 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00070187
- Testing
- aldesleukin, filgrastim, recombinant interferon gamma
- Where
- 63 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Children's Oncology Group
Melanoma, Lymphoma
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: Advanced, which means cancer spread in the body or cannot…
- Conditions
- Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
- Trial name
- NCT02332668
- Testing
- Pembrolizumab
- Where
- 16 sites in United States, Brazil and 8 more
- Volunteers
- 370 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuroblastoma
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma
Neuroblastoma affects approximately 500 children a year in the United States. When the tumor occurs in infants, it is frequently localized and responds well to therapy.
- Trial name
- NCT00186862
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma…
- Conditions
- Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT03441360
- Testing
- Eribulin mesylate
- Where
- 41 sites in United States
- Volunteers
- 23 people
- Sponsor
- Eisai Inc.
Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
- Conditions
- Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma, Liver Cancer, Liver Cancer, Pediatric
- Trial name
- NCT04134559
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Allison O'Neill, MD
Advanced Solid Tumors
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
- Trial name
- NCT05533697
- Testing
- mRNA-4359, Pembrolizumab, Ipilimumab
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 361 people
- Sponsor
- ModernaTX, Inc.
Relapsed/Refractory Acute Leukemia
Expanded Access Program for Revumenib
This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no…
- Trial name
- NCT05918913
- Testing
- Revumenib
- Where
- 35 sites in United States
- Sponsor
- Syndax Pharmaceuticals
Leukemia, Lymphoblastic, Acute, Lymphoma
Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19
This is a multi-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with (1) high risk, relapsed/refractory (r/r) CD19+ B-ALL; (2) r/r…
- Trial name
- ALLCAR19 (NCT02935257)
- Testing
- CD19CAT-41BBZ CAR T-cells
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- University College, London
Hodgkin Lymphoma
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory…
- Trial name
- ANIMATE (NCT03337919)
- Testing
- Nivolumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- University College, London
Acute Myeloid Leukemia
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT05580601
- Testing
- CIML-NK Cells
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Nelarabine has shown significant activity in patients with T-cell malignancies. This study will determine the safety and maximum tolerated dose of the combination of nelarabine, cyclophosphamide and etoposide in patients with…
- Trial name
- NCT00981799
- Testing
- Nelarabine, Etoposide, Cyclophosphamide
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Leukemia, Lymphoma
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and determine a patient's eligibility for a treatment…
- Trial name
- NCT00897767
- Testing
- biologic sample preservation procedure
- Where
- 214 sites in United States
- Volunteers
- 1,873 people
- Sponsor
- Eastern Cooperative Oncology Group
Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3.
- Trial name
- NCT04928677
- Testing
- Codrituzumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-cell Lymphoma
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.
- Trial name
- CARMA-01 (NCT06002659)
- Testing
- CAR20(NAP)-T, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Sweden
- Volunteers
- 18 people
- Sponsor
- Uppsala University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00702403
- Testing
- nilotinib, imatinib mesylate, pharmacological study
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory…
- Trial name
- NCT03896854
- Testing
- CART-19
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.